Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
- 8 April 2022
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 399 (10336), 1695-1707
- https://doi.org/10.1016/s0140-6736(22)00367-1
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerEuropean Urology, 2016
- Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302European Urology, 2016
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2015
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerThe New England Journal of Medicine, 2015
- Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in EuropeEuropean Urology, 2015
- Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitroThe Journal of Steroid Biochemistry and Molecular Biology, 2014
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal ToxicityCancer Research, 2009
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008